Bio-Techne Q3 FY2022 revenue $290.4M (+17% organic), record adj. EPS $2.14

BIO-TECHNE Corp

2022-Q3 EPS reported $5.12 revenue$817,371,000

Q3 organic revenue +17% to $290.4M (reported +19%); YTD organic +18% to $817.4M.
Record adjusted EPS $2.14 (GAAP EPS $1.48) vs $1.80 prior year.
Protein Sciences organic +16%; Diagnostics & Genomics organic +19%.
Declared quarterly dividend $0.32/share, payable May 27 to holders of record May 16.
Announced exclusive agreement with Thermo Fisher to commercialize ExoTRU kidney transplant test.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.